141 Effectiveness of a social network intervention 5 and duration of hospitalization based on medical records obtained over the period from baseline to 12-month follow-up and over the 18-month follow-up period. All analyses were adjusted for the baseline value of the particular outcome and potential confounders (i.e., sex, age, ethnicity, type of forensic outpatient care site, and duration of outpatient treatment). In addition, for the outcomes of hospitalization, we adjusted for hospitalization at baseline. Two-tailed significance level of p < 0.05 was used to assess the magnitude of treatment effects, Cohen’s d effect sizes were calculated for continuous outcomes by dividing the regression coefficients of an outcome by the standard deviation (SD) of the total outcome. Additionally, rate ratios (RR) were calculated for count outcomes and an odds ratio (OR) was calculated for the dichotomous outcome. Finally, moderator analyses were conducted to explore moderators of treatment effects on primary and key secondary outcomes by adding a set of predefined potential moderators (i.e., males/females, age, comorbidity, comorbid intellectual disability, comorbid personality disorder, primary personality disorder, primary psychotic disorder, and primary substance use disorder) as interactions to the analyses. RESULTS Baseline characteristics of participants The participants included in the intention-to-treat sample (N = 102) were predominantly males (88.2%) between 17 and 67 years with a mean age of 40.5 years (SD = 12.8). The largest ethnic groups were white participants (40.2%) and black Caribbean or African participants (23.5%) respectively. Most participants were diagnosed with multiple disorders by clinicians (90.2%). Participants received mandatory treatment (59.8%) at baseline and reported histories of hospitalizations in addiction and/or psychiatric care institutes (63.7%). More baseline characteristics of participants are presented in Table 1. Demographic and clinical characteristics were well balanced between the groups at baseline assessment, with the exception of sex. There were slightly more females randomized to the TAU+FNC group (n = 10), compared to the TAU group (n = 3). In addition, the duration of TAU was not significantly different between treatment groups at 12-months follow-up (Mann-Whitney U = 980.5, p = 0.757), as well as at 18-months follow-up (Mann-Whitney U = 894.0, p = 0.802). Participants in the TAU+FNC group received TAU for an average of 9.9 months (SD = 3.5) at 12-month follow-up and 12.8
RkJQdWJsaXNoZXIy MjY0ODMw